Home / Stock ratings / Healthcare Stocks / ELV
Stock rating · Hospital & Medical Service Plans
Elevance Health, Inc. (ELV) Stock Rating & Analysis
As of October 6, 2026, MELANY rates Elevance Health, Inc. 71 out of 100 (Highest Conviction). Its highest factor score is catalyst setup at 100, and its lowest is business quality at 40.
MELANY ratingRated 2026-10-06ELV · composite score
About Elevance Health, Inc.
Elevance Health is among the leading US health insurers, providing medical benefits to 45 million medical members at the end of 2025 through employer, individual, and government-sponsored plans. It is distinguished as the largest single provider of Blue Cross Blue Shield branded coverage, operating as the Blue Cross Blue Shield Association licensee in 14 states.
Rating as of 2026-10-06 · this is a dated snapshot; the live rating is in the app (Pro, free for 30 days). The price above updates in real time.
Why ELV scores 71/100
ELV's 8 factor scores run from 40 to 100, and 3 of them sit above its composite of 71. Here is how ELV breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
- P/E 17.7x vs sector 22.0x median
Margins, returns on capital, and balance-sheet strength.
Direction and relative strength of the recent share-price trend.
- 50-day MA above 200-day (golden cross zone)
History of beating or missing estimates, and where estimates are heading.
- Beat EPS estimates 4 of last 4 quarters
- Avg EPS beat +15%
- Earnings in 15 days (strong beat history)
What Wall Street price targets and revisions are signalling.
Near-term events that could move the stock.
- Earnings in 15 days
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
How ELV compares
As of October 7, 2026, Elevance Health, Inc. is tied for 4th of 20 in Healthcare Stocks, where the average score is 67.
Key risks for ELV
- No specific company-level red flags detected, monitor macro regime changes
Sector and theme context
Elevance Health, Inc. sits in the Healthcare sector theme, which MELANY currently rates 37/100 for strength. Theme strength feeds ELV's momentum and catalyst factors above.
ELV trade plan (Pro)
MELANY has a full position plan for Elevance Health, Inc.: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It is part of Market Eyes Pro, and the first 30 days are free.
How MELANY rates ELV
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Elevance Health, Inc.'s 71/100 reflects mature factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about ELV
Is Elevance Health, Inc. (ELV) a buy?
As of 2026-10-06, MELANY rated Elevance Health, Inc. Highest Conviction with a composite score of 71/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Elevance Health, Inc.'s MELANY score?
Elevance Health, Inc. (ELV) has a MELANY composite score of 71/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, macro fit.
How is the ELV stock rating calculated?
MELANY scores ELV from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy Elevance Health, Inc. stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Elevance Health, Inc. (ELV) Highest Conviction with a composite of 71/100 as of 2026-10-06. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the ELV stock price forecast?
MELANY does not publish price targets or forecasts for ELV. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 71/100 across eight factors for Elevance Health, Inc., and re-scores automatically as new price, earnings, and fundamental data arrive.
Is ELV stock overvalued or undervalued?
MELANY's valuation factor currently reads 70/100 for Elevance Health, Inc., where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives ELV's read.
What price should I buy ELV at?
Rather than chasing the current price, MELANY computes a smart entry zone for ELV: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels are part of Market Eyes Pro, which starts with a 30-day free trial.
What are the risks of buying ELV stock?
The top risks MELANY currently flags for Elevance Health, Inc.: No specific company-level red flags detected, monitor macro regime changes. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Elevance Health, Inc. a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 40/100 for Elevance Health, Inc., and earnings track record, at 92/100. The 71/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will ELV stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 65/100 for ELV right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this ELV rating?
The rating on this page is a snapshot of MELANY's read as of 2026-10-06. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores ELV continuously as new price, earnings, and fundamental data arrive, and the current rating is in the app (Pro, free for 30 days).
How this rating works
Market Eyes Live
Every rating graded in public, ELV included
MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.